Incb062079

Nasopharyngeal Cancer

Incyte CorporationPhase 1Dormant

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

44 Active assets in the Nasopharyngeal Cancer cohort.

Asset / Sponsor	Phase	Rating
Eloxatin National Cancer Institute (NCI)	Phase 2	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	B
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	B
Ipilimumab Xencor, Inc.	Phase 2	B
[68ga]ga-nota-t4 RenJi Hospital	Phase 2/3	B